TNF and osteosarcoma: Indeed, the presumed deficiency in TNFα-producing tumor-associated myeloid cells within SCID mice probably explains the relatively poor anti-osteosarcoma efficacy of LCL161 in treating SCID mice bearing patient-derived xenografts [21].